Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform's ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. The demonstration underscores the company's push to commercialize its AI technology, which is now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company.
The withZeta.ai platform is part of Lantern's broader strategy to leverage artificial intelligence and machine learning in precision oncology. The company's proprietary RADR platform underpins its drug development efforts, including clinical candidates LP-184, LP-284, and LP-300. LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary, while LP-300 is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma.
The live demo is expected to provide investors and researchers with a firsthand look at how withZeta.ai can streamline research workflows, potentially reducing the time and cost associated with bringing new cancer therapies to market. For more details, the full press release is available at https://ibn.fm/wzevl.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company's latest news and updates can be found in its newsroom at https://ibn.fm/LTRN.
